| WO1995032003A1 (en)* | 1994-05-24 | 1995-11-30 | Amgen Boulder Inc. | Modified insulin-like growth factors |
| US7153943B2 (en) | 1997-07-14 | 2006-12-26 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins, and methods of use thereof |
| US20080076706A1 (en) | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
| WO1999003887A1 (en) | 1997-07-14 | 1999-01-28 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| US7495087B2 (en) | 1997-07-14 | 2009-02-24 | Bolder Biotechnology, Inc. | Cysteine muteins in the C-D loop of human interleukin-11 |
| AU6515499A (en)* | 1998-10-16 | 2000-05-08 | Musc Foundation For Research Development | Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof |
| US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| BR0008759B1 (en) | 1999-01-14 | 2014-03-11 | Bolder Biotechnology Inc | Methods for the production of protein containing free cysteine residues |
| WO2000050067A1 (en)* | 1999-02-26 | 2000-08-31 | Saltech I Göteborg Ab | Method and composition for the regulation of hepatic and extrahepatic production of insulin-like growth factor-1 |
| AUPR030900A0 (en)* | 2000-09-22 | 2000-10-12 | Queensland University Of Technology | Growth factor complex |
| US20040186051A1 (en) | 2001-10-02 | 2004-09-23 | Kelley Robert F | Apo-2 ligand variants and uses thereof |
| JP4574350B2 (en) | 2002-06-24 | 2010-11-04 | ジェネンテック， インコーポレイテッド | APO-2 ligand / TRAIL variant and methods of use thereof |
| CA2541015A1 (en) | 2003-10-03 | 2005-04-14 | Genentech, Inc. | Igf binding proteins |
| WO2007041614A2 (en) | 2005-10-03 | 2007-04-12 | Bolder Biotechnology, Inc. | Long acting vegf inhibitors and methods of use |
| WO2008019491A1 (en)* | 2006-08-16 | 2008-02-21 | National Research Council Of Canada | Inhibition of angiogenesis, tumorigenesis and cathepsin activity using insulin-like growth factor binding protein |
| BR112016002845A2 (en) | 2013-08-12 | 2017-09-12 | Genentech Inc | compositions and methods for treating complement-associated conditions |
| BR112016025312A2 (en) | 2014-05-01 | 2017-10-17 | Genentech Inc | antibody variants, anti-d-factor antibody, pharmaceutical formulation, dispensing device, use of the formulation and a composition, composition and method of treating a disorder |
| JP2018536650A (en) | 2015-10-30 | 2018-12-13 | ジェネンテック， インコーポレイテッド | Anti-factor D antibody variant conjugates and uses thereof |
| EP3368074A2 (en) | 2015-10-30 | 2018-09-05 | Hoffmann-La Roche AG | Anti-factor d antibodies and conjugates |
| EP3534932B1 (en)* | 2016-11-01 | 2024-05-22 | Virginia Commonwealth University | Treatment of diseases related to igfb3 and its receptor |
| JP2023519213A (en) | 2020-03-24 | 2023-05-10 | ジェネンテック， インコーポレイテッド | TIE2 binding agents and methods of use |
| CN116144667B (en)* | 2022-12-29 | 2024-03-12 | 海南大学 | Gene, protein and application of insulin-like growth factor binding protein 1 in Pomfret ovata |